FDA Submission Update for COSENTYX (Secukinumab) by Novartis
Novartis has submitted a supplemental application for COSENTYX (Secukinumab) under BLA761349, currently under standard review.
Asset / Drug
Drug and asset intelligence for COSENTYX with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved a supplemental application for Cosentyx (Secukinumab) submitted by Novartis.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.